Phospho-NTRK2 (Tyr706/Tyr707) Antibody

What is the functional significance of NTRK2 phosphorylation at Tyr706/707?

Phosphorylation of NTRK2 (TrkB) at Tyr706/707 represents a critical autophosphorylation event that occurs following ligand binding, particularly by Brain-Derived Neurotrophic Factor (BDNF). This phosphorylation is essential for initiating downstream signaling cascades that regulate neuronal survival, differentiation, and synaptic plasticity. When BDNF binds to TrkB, it triggers dimerization of the receptor, activating its intrinsic tyrosine kinase activity and resulting in autophosphorylation at multiple tyrosine residues including Tyr706/707 . This phosphorylation creates binding sites for adaptor proteins and signaling molecules that activate pathways such as MAPK/ERK, PI3K/Akt, and PLCγ . The importance of this phosphorylation site is underscored by studies showing that loss of TrkB signaling through genetic knockout significantly impairs neurogenesis and alters glial differentiation patterns .

How does NTRK2 phosphorylation differ between Tyr706/707 and other phosphorylation sites like Tyr516?

NTRK2 contains multiple phosphorylation sites that serve distinct but complementary functions in signal transduction. Tyr706/707 phosphorylation occurs within the activation loop of the tyrosine kinase domain and is directly associated with catalytic activation of the receptor . In contrast, Tyr516 phosphorylation creates a binding site primarily for adaptor proteins like Shc, which links TrkB to the Ras/MAPK pathway . The functional distinction is evident in experimental settings where phosphorylation-specific antibodies detect different downstream effects: phospho-TrkB (Y706) antibodies reveal broader downstream kinase activation patterns, including phosphorylation of PLCG1 (Tyr771/775), JAK2 (Tyr570), and MAP kinases . Immunoblotting experiments demonstrate that these phosphorylation events follow different kinetics and may be differentially regulated in various neuronal populations and pathological conditions .

What are the primary ligands that induce NTRK2 phosphorylation at Tyr706/707?

While Brain-Derived Neurotrophic Factor (BDNF) is the principal high-affinity ligand for TrkB, neurotrophins NT-3 and NT-4/5 can also bind to and activate the receptor, inducing phosphorylation at Tyr706/707 . BDNF binding triggers the most robust phosphorylation response, with studies showing significant increases in phospho-ERK levels and other downstream targets following BDNF treatment in wild-type neural cells . Interestingly, ReNcell VM studies reveal that these cells may secrete basal levels of BDNF or other TrkB-activating factors, resulting in substantial constitutive TrkB phosphorylation even without exogenous ligand addition . The differential activation by these neurotrophins contributes to the precise regulation of neuronal development and function across various brain regions and developmental stages.

What experimental techniques can effectively utilize Phospho-NTRK2 (Tyr706/707) antibodies?

Phospho-NTRK2 (Tyr706/707) antibodies can be employed across multiple experimental platforms, each offering distinct advantages for investigating TrkB activation. The most common applications include:

For optimal results, validation experiments should confirm antibody specificity using appropriate controls, including NTRK2 knockout cells as demonstrated in ReNcell VM studies, where phospho-ERK was drastically diminished in NTRK2-deficient cells even following BDNF treatment .

How can Phospho-NTRK2 antibodies be used to study neural development and differentiation?

Phospho-NTRK2 antibodies serve as powerful tools for investigating the role of TrkB signaling in neural development and differentiation. Researchers can design experiments that monitor changes in TrkB phosphorylation during:

• Neural progenitor cell differentiation: By collecting samples at different time points during differentiation (e.g., days 0 and 5), researchers can track how TrkB activation correlates with the expression of neurogenic transcription factors and early glial progenitor markers .

• Lineage commitment studies: CRISPR/Cas9-mediated knockout of NTRK2, combined with phospho-TrkB immunostaining, reveals that TrkB activation promotes neurogenesis while inhibiting glial differentiation, as demonstrated by decreased expression of key neurogenic transcription factors and enrichment of glial progenitor markers in NTRK2-deficient cells .

• Regional brain development: Immunohistochemical analysis using phospho-TrkB antibodies can map the spatiotemporal activation patterns of TrkB during brain development, correlating receptor activation with neurite outgrowth, synaptogenesis, and circuit formation .

When designing such experiments, researchers should consider that TrkB activation involves multiple downstream pathways, and phosphorylation at Tyr706/707 may drive distinct signaling outcomes in different neural cell populations or developmental stages.

What are the best practices for studying phosphorylation dynamics using these antibodies?

To accurately capture the dynamic nature of NTRK2 phosphorylation at Tyr706/707, researchers should implement the following best practices:

• Time-course experiments: Design temporal studies that capture rapid phosphorylation events (seconds to minutes) as well as sustained activation (hours to days). BDNF stimulation typically induces detectable phosphorylation within minutes, with peak activation often occurring at 15-30 minutes .

• Phosphatase inhibitors: Include phosphatase inhibitors (e.g., sodium orthovanadate, sodium fluoride) in all sample preparation buffers to prevent dephosphorylation during cell lysis and protein extraction .

• Signal quantification: Use densitometry to quantify Western blot signals, normalizing phospho-TrkB levels to total TrkB protein rather than housekeeping proteins to account for variations in receptor expression .

• Parallel pathway analysis: Monitor multiple downstream effectors (e.g., phospho-ERK, phospho-PLCγ1, phospho-Akt) simultaneously to develop a comprehensive understanding of pathway activation following TrkB phosphorylation .

• Complementary methodologies: Combine antibody-based detection with functional kinase assays that measure the enzymatic activity of TrkB following phosphorylation, as demonstrated in studies using peptide arrays to assess phosphorylation of TrkB targets .

What are the critical factors affecting specificity when using Phospho-NTRK2 (Tyr706/707) antibodies?

Ensuring specificity when working with phospho-specific antibodies requires careful attention to several factors:

• Antibody validation: Confirm specificity using appropriate controls, including:

  • NTRK2 knockout cells or tissues, which should show no signal

  • Dephosphorylated samples (treated with phosphatases)

  • Peptide competition assays using the immunizing phosphopeptide

• Cross-reactivity assessment: Test for potential cross-reactivity with related phosphorylated tyrosine kinase receptors (e.g., TrkA, TrkC) or with unphosphorylated TrkB. Commercial antibodies should be validated to detect TrkB protein only when phosphorylated at specific residues (Y706) .

• Sample preparation: Rapid sample processing is crucial to preserve phosphorylation status. Cell lysis and protein extraction should be performed at 4°C with appropriate phosphatase inhibitors to prevent artificial dephosphorylation .

• Signal verification: Confirm the identity of detected bands or signals by comparing them with expected molecular weights. For TrkB, multiple isoforms may be detected (as observed in ReNcell VM immunoblotting studies) , and phosphorylation may alter the apparent molecular weight.

When interpreting results, researchers should be aware that most Tyr706/707 antibodies cannot distinguish between single and dual phosphorylation events at these adjacent residues.

How can researchers address technical challenges in detecting low levels of phosphorylated NTRK2?

Detecting low-abundance phosphorylated NTRK2 presents significant technical challenges that can be addressed through several optimization strategies:

• Signal enhancement methods:

  • Implement tyramide signal amplification for immunohistochemistry and immunofluorescence

  • Use high-sensitivity chemiluminescent substrates for Western blotting

  • Consider biotin-streptavidin amplification systems when appropriate

• Enrichment techniques:

  • Perform immunoprecipitation of total TrkB followed by phospho-specific detection

  • Use phosphotyrosine-specific enrichment (e.g., anti-pTyr antibody pulldown) prior to TrkB-specific detection

  • Consider size-exclusion chromatography to concentrate receptor fractions

• Receptor activation enhancement:

  • Pre-treat samples with pervanadate to inhibit tyrosine phosphatases

  • Stimulate cells with high concentrations of BDNF (50-100 ng/ml) to maximize receptor phosphorylation

  • Use serum starvation prior to stimulation to reduce baseline phosphorylation of other proteins

• Detection optimization:

  • Adjust antibody concentration and incubation conditions (time, temperature)

  • Optimize blocking conditions to reduce background while preserving specific signals

  • Consider alternative detection methods like proximity ligation assay (PLA) for increased sensitivity

When applying these strategies, it's important to include appropriate positive controls (e.g., BDNF-stimulated samples) and negative controls (e.g., NTRK2-deficient cells) to accurately interpret results.

What methodological approaches can differentiate between basal and ligand-induced NTRK2 phosphorylation?

Distinguishing between basal and ligand-induced NTRK2 phosphorylation requires carefully designed experimental approaches:

• Temporal analysis with precise controls:

  • Implement strict serum starvation protocols (12-24 hours) to reduce basal phosphorylation

  • Include untreated controls alongside ligand-stimulated samples

  • Use a time-course of ligand stimulation (e.g., 5, 15, 30, 60 minutes) to capture the kinetics of induced phosphorylation

• Pharmacological interventions:

  • Apply TrkB inhibitors to establish true baseline by blocking constitutive activity

  • Use neutralizing antibodies against endogenous BDNF to determine the contribution of autocrine/paracrine signaling to basal phosphorylation

  • Consider inhibitors of specific downstream pathways to determine which signaling branches are active in basal versus stimulated conditions

• Quantitative comparisons:

  • Calculate fold-change in phosphorylation relative to baseline using densitometry

  • Normalize phospho-TrkB signals to total TrkB rather than loading controls

  • Consider using phospho-to-total TrkB ratios for more accurate quantification

• Complementary functional assays:

  • Compare downstream signaling activation (e.g., ERK phosphorylation, PLCγ1 phosphorylation) between basal and stimulated conditions

  • Implement kinase activity profiling as demonstrated in ReNcell VM studies, which showed significant differences in the phosphorylation of target peptides between wild-type and NTRK2-deficient cells

Research with ReNcell VM cells has shown that they secrete basal levels of BDNF or other TrkB-activating factors, leading to substantial constitutive phosphorylation , highlighting the importance of appropriate controls in accurately interpreting phosphorylation data.

How can Phospho-NTRK2 (Tyr706/707) antibodies be utilized in cancer research, particularly for tumors with NTRK gene fusions?

NTRK gene fusions, including those involving NTRK2, have emerged as important oncogenic drivers in various cancers, including low-grade gliomas as described in the literature . Phospho-NTRK2 antibodies provide valuable tools for investigating these malignancies through several approaches:

• Diagnostic biomarker development:

  • Immunohistochemical detection of phosphorylated TrkB can help identify tumors with activated NTRK2 signaling, potentially indicating the presence of fusion proteins

  • Western blot analysis can reveal altered phosphorylation patterns or molecular weight shifts characteristic of specific fusion proteins, such as the novel PML-NTRK2 fusion described in pilocytic astrocytoma

• Therapeutic response monitoring:

  • Evaluation of TrkB phosphorylation status before and after treatment with TRK inhibitors to assess target engagement

  • Correlation of phosphorylation levels with clinical outcomes to identify responder populations

  • Investigation of resistance mechanisms through altered phosphorylation patterns

• Fusion protein characterization:

  • Analysis of phosphorylation status of fusion proteins compared to wild-type TrkB

  • Investigation of whether fusion proteins exhibit constitutive phosphorylation at Tyr706/707

  • Assessment of differential activation of downstream signaling pathways by fusion proteins versus ligand-activated wild-type receptors

• Preclinical model validation:

  • Verification of TrkB activation status in patient-derived xenografts or cell lines harboring NTRK2 fusions

  • Evaluation of phosphorylation dynamics in response to targeted therapies in these models

When studying NTRK2 fusions, researchers should be aware that fusion proteins may exhibit altered epitope accessibility or phosphorylation patterns compared to wild-type TrkB, potentially requiring optimization of antibody-based detection methods.

What approaches can combine Phospho-NTRK2 antibodies with genetic manipulation techniques for mechanistic studies?

Integrating phospho-NTRK2 antibody detection with genetic manipulation techniques provides powerful approaches for mechanistic studies:

The ReNcell VM NTRK2 knockout model demonstrates the utility of this approach, revealing that loss of TrkB signaling fundamentally alters the expression profile of genes involved in neurogenesis and glial differentiation .

How can researchers correlate Phospho-NTRK2 levels with functional cellular outcomes like mitochondrial activity?

Correlating phospho-NTRK2 levels with functional cellular outcomes requires multi-parameter experimental designs that link receptor activation to specific downstream processes:

• Mitochondrial function analysis:

  • Implement Seahorse XF Cell Mito Stress Tests to measure oxygen consumption rate (OCR) in cells with varying levels of TrkB activation, as demonstrated in the comparison of wild-type and NTRK2-knockout ReNcell VM cells

  • Assess mitochondrial membrane potential using fluorescent probes in relation to TrkB phosphorylation status

  • Evaluate ATP production rates and glycolytic function in response to BDNF stimulation or TrkB inhibition

• Metabolic profiling:

  • Combine phospho-TrkB detection with metabolomic analyses to identify metabolites that correlate with receptor activation

  • Assess glucose uptake, lactate production, and glutamine metabolism in relation to TrkB phosphorylation status

  • Investigate the role of TrkB in regulating mitochondrial biogenesis through analysis of mitochondrial DNA content and expression of biogenesis factors

• Functional pathway analysis:

  • Implement inhibitors of specific downstream pathways (e.g., MEK/ERK, PI3K/Akt, PLCγ) to determine which signaling branches mediate the effects of TrkB phosphorylation on mitochondrial function

  • Use pathway-specific reporter assays to correlate TrkB phosphorylation with activation of transcription factors governing metabolic gene expression

  • Assess phosphorylation of mitochondrial proteins in response to TrkB activation to identify direct links between receptor signaling and organelle function

• Single-cell correlation approaches:

  • Apply flow cytometry or imaging cytometry to simultaneously assess phospho-TrkB levels and mitochondrial parameters in individual cells

  • Implement live-cell imaging with fluorescent reporters to track TrkB phosphorylation and mitochondrial dynamics in real-time

Research with NTRK2-knockout ReNcell VM cells has begun to explore these relationships, showing trends in mitochondrial function between wild-type and knockout cells, although the differences did not reach statistical significance in the reported studies .

How should researchers interpret conflicting results between phosphorylation at different TrkB tyrosine residues?

When faced with conflicting results between phosphorylation at different TrkB tyrosine residues (e.g., Tyr706/707 vs. Tyr516), researchers should consider several interpretative frameworks:

• Differential activation mechanisms:

  • Different ligands or concentrations may preferentially induce phosphorylation at specific residues

  • Autophosphorylation may follow a sequential pattern, with certain residues being phosphorylated earlier than others

  • Trans-phosphorylation by other kinases may target specific residues independently of TrkB's intrinsic kinase activity

• Pathway-specific regulation:

  • Tyr706/707 phosphorylation primarily reflects catalytic activation status , while Tyr516 phosphorylation creates docking sites for specific adaptor proteins

  • Different phosphatases may preferentially target specific phosphorylation sites, leading to distinct temporal patterns

  • Scaffold proteins or regulatory factors may selectively enhance or inhibit phosphorylation at particular residues

• Technical considerations:

  • Antibody affinity and specificity differences may create apparent discrepancies

  • Steric hindrance from protein interactions may mask epitope accessibility at certain phosphorylation sites

  • Sample preparation methods may differentially preserve phosphorylation at various residues

• Biological context variations:

  • Cell type-specific or developmental stage-specific factors may influence the pattern of TrkB phosphorylation

  • Pathological conditions may alter the typical relationship between phosphorylation at different residues

To address these conflicts, researchers should implement multiple detection methods, perform time-course experiments, and use pharmacological or genetic interventions to decipher the relationship between different phosphorylation events.

What control experiments are essential when publishing research using Phospho-NTRK2 antibodies?

When publishing research utilizing phospho-NTRK2 antibodies, the following control experiments are essential to ensure validity and reproducibility:

• Antibody validation controls:

  • Genetic knockout or knockdown of NTRK2 to demonstrate antibody specificity, as exemplified in the ReNcell VM studies where phospho-signals were dramatically reduced in NTRK2-deficient cells

  • Phosphatase treatment of samples to confirm phospho-specificity

  • Peptide competition assays using phosphorylated and non-phosphorylated peptides

  • Comparison of multiple antibody clones targeting the same phosphorylation site when available

• Biological activity controls:

  • Positive controls using BDNF or other known TrkB activators to demonstrate maximal phosphorylation

  • Negative controls using TrkB kinase inhibitors to establish baseline

  • Time-course experiments showing the expected temporal pattern of phosphorylation

  • Dose-response experiments demonstrating the relationship between ligand concentration and phosphorylation levels

• Technical quality controls:

  • Total TrkB protein detection in parallel with phospho-specific detection

  • Loading controls appropriate for the experimental system

  • Quantification of signal with appropriate statistical analysis

  • Reproducibility across multiple biological replicates (generally at least three independent experiments)

• Functional correlation controls:

  • Demonstration that phosphorylation correlates with expected downstream signaling events, such as ERK activation

  • Functional assays that confirm the biological relevance of observed phosphorylation changes

Including these controls not only strengthens the validity of the research but also provides valuable troubleshooting resources for other researchers in the field.

What experimental design approaches can effectively compare phosphorylation patterns across different neural cell types or brain regions?

To effectively compare TrkB phosphorylation patterns across neural cell types or brain regions, researchers should implement comprehensive experimental designs that account for biological and technical variables:

• Cross-platform validation approach:

  • Implement multiple detection methods (e.g., Western blot, immunohistochemistry, ELISA) on the same samples to ensure consistency

  • Apply tissue clearing techniques combined with 3D imaging for whole-brain phosphorylation mapping

  • Use phospho-proteomics to provide unbiased assessment of phosphorylation patterns across brain regions

• Standardized stimulation protocols:

  • Apply identical BDNF concentrations and stimulation times across all cell types/regions

  • Include both acute (minutes to hours) and chronic (days) stimulation paradigms

  • Control for region-specific differences in endogenous BDNF expression that might affect basal phosphorylation

• Cellular resolution approaches:

  • Implement single-cell phospho-flow cytometry to quantify phospho-TrkB levels in defined cell populations

  • Use fluorescence-activated cell sorting (FACS) to isolate specific cell types prior to biochemical analysis

  • Apply multiplex immunofluorescence to simultaneously visualize cell-type markers and phospho-TrkB

• Developmental timeline consideration:

  • Design experiments that capture TrkB phosphorylation across developmental stages

  • Include age-matched samples when comparing different brain regions

  • Consider the differential timing of neurogenesis and gliogenesis across brain regions when interpreting results

• Genetic background control:

  • Use isogenic cell lines or animals when possible

  • Consider sex as a biological variable when designing experiments

  • Control for genetic polymorphisms that might affect TrkB expression or function

These approaches allow for rigorous comparison while accounting for the inherent variability in TrkB expression and activity across neural cell types and brain regions, as suggested by findings regarding the differential effects of TrkB signaling on neurogenesis versus gliogenesis .